StocksFundsScreenerSectorsWatchlists
BMRN

BMRN - BioMarin Pharmaceutical Inc Stock Price, Fair Value and News

92.25USD+0.79 (+0.86%)Market Closed

Market Summary

BMRN
USD92.25+0.79
Market Closed
0.86%

BMRN Alerts

  • 3 major insider sales recently.

BMRN Stock Price

View Fullscreen

BMRN RSI Chart

BMRN Valuation

Market Cap

17.4B

Price/Earnings (Trailing)

103.82

Price/Sales (Trailing)

7.19

EV/EBITDA

58.57

Price/Free Cashflow

278.18

BMRN Price/Sales (Trailing)

BMRN Profitability

Operating Margin

78.72%

EBT Margin

7.79%

Return on Equity

3.39%

Return on Assets

2.45%

Free Cashflow Yield

0.36%

BMRN Fundamentals

BMRN Revenue

Revenue (TTM)

2.4B

Rev. Growth (Yr)

20.22%

Rev. Growth (Qtr)

11.16%

BMRN Earnings

Earnings (TTM)

167.6M

Earnings Growth (Yr)

8.3K%

Earnings Growth (Qtr)

-49.54%

Breaking Down BMRN Revenue

Last 7 days

6.1%

Last 30 days

8.8%

Last 90 days

-1.2%

Trailing 12 Months

-6.2%

How does BMRN drawdown profile look like?

BMRN Financial Health

Current Ratio

2.51

Debt/Equity

0.12

Debt/Cashflow

0.27

BMRN Investor Care

Shares Dilution (1Y)

1.15%

Diluted EPS (TTM)

0.87

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20232.2B2.2B2.3B2.4B
20221.9B1.9B2.0B2.1B
20211.8B1.9B1.8B1.8B
20201.8B1.8B1.9B1.9B
20191.5B1.5B1.6B1.7B
20181.4B1.4B1.5B1.5B
20171.2B1.2B1.3B1.3B
2016923.7M973.7M1.0B1.1B
2015801.0M859.3M891.7M889.9M
2014572.1M627.1M666.8M749.6M
2013512.0M524.8M533.5M548.5M
2012448.6M461.9M476.6M500.7M
2011400.8M419.5M435.1M441.4M
2010335.6M344.8M361.7M376.3M
20090305.9M315.3M324.7M
2008000296.5M

Tracking the Latest Insider Buys and Sells of BioMarin Pharmaceutical Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Apr 10, 2024
burkhart erin
sold
-205,740
90.00
-2,286
gvp, chief accounting officer
Mar 28, 2024
davis george eric
sold
-2,173,340
88.34
-24,602
evp, chief legal officer
Mar 18, 2024
slamon dennis
acquired
797,000
79.7
10,000
-
Mar 18, 2024
burkhart erin
sold (taxes)
-31,199
83.87
-372
gvp, chief accounting officer
Mar 18, 2024
slamon dennis
sold (taxes)
-797,033
83.81
-9,510
-
Mar 15, 2024
guyer charles greg
acquired
-
-
10,550
evp, chief technical officer
Mar 15, 2024
mueller brian
sold (taxes)
-1,743,570
83.87
-20,789
evp, chief financial officer
Mar 15, 2024
fuchs henry j
sold (taxes)
-2,808,390
83.87
-33,485
president, worldwide r&d
Mar 15, 2024
bienaime jean jacques
sold (taxes)
-7,146,480
83.87
-85,209
-
Mar 15, 2024
davis george eric
acquired
-
-
10,260
evp, chief legal officer

1–10 of 50

Which funds bought or sold BMRN recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Apr 11, 2024
City State Bank
unchanged
-
-2,000
17,000
0.01%
Apr 11, 2024
SALEM INVESTMENT COUNSELORS INC
sold off
-100
-13,981
-
-%
Apr 11, 2024
Gulf International Bank (UK) Ltd
added
0.65
-137,000
1,418,000
0.04%
Apr 11, 2024
Fortitude Family Office, LLC
reduced
-78.05
-3,167
786
-%
Apr 11, 2024
TEALWOOD ASSET MANAGEMENT INC
reduced
-1.81
-132,000
1,066,000
0.48%
Apr 11, 2024
SANDERS MORRIS HARRIS LLC
unchanged
-
-46,496
349,360
0.06%
Apr 10, 2024
PARK AVENUE SECURITIES LLC
reduced
-25.46
-195,000
403,000
-%
Apr 10, 2024
CVA Family Office, LLC
unchanged
-
-454
4,367
-%
Apr 10, 2024
Banque Cantonale Vaudoise
reduced
-2.47
-189,000
1,428,000
0.06%
Apr 10, 2024
Bruce G. Allen Investments, LLC
unchanged
-
-146
1,397
-%

1–10 of 45

Are Funds Buying or Selling BMRN?

Are funds buying BMRN calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own BMRN
No. of Funds

Unveiling BioMarin Pharmaceutical Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2024
dodge & cox
7.4%
13,994,063
SC 13G/A
Feb 13, 2024
vanguard group inc
9.58%
18,048,557
SC 13G/A
Feb 12, 2024
primecap management co/ca/
9.78%
18,414,374
SC 13G/A
Feb 09, 2024
capital research global investors
5.7%
10,774,641
SC 13G
Jan 26, 2024
blackrock inc.
7.8%
14,740,836
SC 13G/A
Feb 14, 2023
dodge & cox
7.7%
14,383,663
SC 13G/A
Feb 13, 2023
capital research global investors
3.0%
5,651,001
SC 13G/A
Feb 09, 2023
primecap management co/ca/
9.46%
17,580,859
SC 13G/A
Feb 09, 2023
vanguard group inc
9.34%
17,365,080
SC 13G/A
Feb 03, 2023
blackrock inc.
8.2%
15,206,690
SC 13G/A

Recent SEC filings of BioMarin Pharmaceutical Inc

View All Filings
Date Filed Form Type Document
Apr 12, 2024
144
Notice of Insider Sale Intent
Apr 12, 2024
4
Insider Trading
Apr 11, 2024
144
Notice of Insider Sale Intent
Apr 10, 2024
144
Notice of Insider Sale Intent
Apr 09, 2024
ARS
ARS
Apr 09, 2024
DEF 14A
DEF 14A
Apr 09, 2024
DEFA14A
DEFA14A
Apr 01, 2024
4
Insider Trading
Mar 28, 2024
144
Notice of Insider Sale Intent
Mar 20, 2024
4
Insider Trading

Peers (Alternatives to BioMarin Pharmaceutical Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
40.2B
6.8B
-1.24% -34.47%
-8.53
5.87
-64.45% -156.37%
22.4B
152.6K
-0.77% 465779.94%
-2.4K
146.8K
- -9.98%
18.7B
1.8B
0.05% -28.38%
-42.48
10.23
76.23% 61.08%
17.4B
2.4B
8.82% -6.19%
103.82
7.19
15.42% 18.43%
12.1B
3.7B
-8.57% -28.49%
20.24
3.27
8.87% 75.42%
MID-CAP
6.2B
396.6M
-9.73% -34.59%
-11.81
15.74
425.83% 18.94%
4.7B
-
-4.69% 71.46%
-7.23
60.35
54.84% -34.79%
3.3B
270.6M
-0.99% 6.40%
-13.71
12.12
440.80% -27.84%
3.1B
240.7M
-13.54% -18.95%
-10.32
12.72
-1.03% -92.09%
2.8B
726.4M
-12.42% -7.51%
-46.06
3.89
40.45% 71.62%
SMALL-CAP
1.8B
398.2M
-8.48% -15.36%
25.1
4.5
85.90% -14.05%
599.0M
983.7M
-18.48% -55.04%
-1.1
0.61
-50.36% 17.16%
428.3M
881.7K
-13.30% 407.71%
-9.6
466.16
-77.61% -5.33%
257.8M
4.9M
-1.96% -2.22%
-1.91
52.97
-54.97% 51.72%
7.2M
2.1M
77.59% 88.99%
-0.26
2.14
-13.45% 66.37%

BioMarin Pharmaceutical Inc News

Latest updates
Defense World15 hours ago
StockNews.com10 Apr 202402:07 pm

BioMarin Pharmaceutical Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Revenue11.2%646581595596538505534519450409502486452477429502454461388401353
Cost Of Revenue8.6%13512512812712711612311712010412712012618998.0011196.0097.0077.0089.0075.00
Costs and Expenses13.7%632556536537562508495382516462490461504533470397464457429455391
  S&GA Expenses22.8%275224215223246217197195218183184174196179175187188170161162164
  R&D Expenses7.8%206191177172173158158161161158161149157147182142173173186184175
EBITDA Margin11.2%0.12*0.11*0.09*0.08*0.12*0.10*0.08*0.08*0.02*0.02*0.02*0.00*---------
Interest Expenses61.4%6.004.004.004.004.005.004.004.004.004.004.004.005.0010.008.007.007.003.007.007.008.00
Income Taxes-181.2%-1.051.0015.006.00-17.315.007.0013.00-8.68-9.671.006.00-63.89-846-13.0920.00-24.80-45.21-4.464.00-39.66
Earnings Before Taxes-53.6%19.0042.0071.0057.00-17.56-1.9035.00134-66.57-46.1614.0023.00-46.86-61.22-42.27101-9.7810.00-41.89-52.96-43.31
EBT Margin18.7%0.08*0.07*0.05*0.03*0.07*0.05*0.03*0.02*-0.04*-0.03*-0.04*-0.07*---------
Net Income-49.5%20.0040.0056.0051.00-0.25-6.6528.00121-57.90-36.4913.0017.0017.00785-29.1881.0015.0055.00-37.43-56.47-3.65
Net Income Margin8.9%0.07*0.06*0.04*0.03*0.07*0.04*0.03*0.02*-0.03*0.01*0.43*0.43*---------
Free Cashflow-101.3%-1.4311448.00-98.39-28.9012929.00-74.25-17.5678.0060.0088.00---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Assets1.2%6,8426,7586,5636,4346,3756,2646,1466,0636,0055,9775,8985,8055,8486,1585,3024,7234,6904,5584,3934,4354,427
  Current Assets0.0%2,9562,9552,9502,8422,7512,6832,5182,3942,2742,3122,3582,2892,3422,7392,6482,1161,9421,8591,8071,9172,056
    Cash Equivalents-3.9%7557856945807257626206055876176426676491,016819477437423308364494
  Inventory7.3%1,1071,032976919894839802786777749711714699701744706680609579535531
  Net PPE-0.1%1,0661,0671,0671,0681,0731,0521,0491,0401,0351,0251,0271,0221,0321,0151,0111,0101,011969963952949
  Goodwill0%196196196196196196196196196196196196196196196196197197197197197
Liabilities1.5%1,8901,8611,7801,7751,7721,6961,6411,6711,7391,7111,6571,6431,7422,1042,0651,4831,5681,4841,4321,4991,459
  Current Liabilities1.2%1,1771,163597598589521465490546515443430493855813820933494439501523
  Long Term Debt0.1%5935931,0851,0841,0831,0821,0811,0801,0791,0781,0771,0761,0751,0741,073487486844839835830
    LT Debt, Current0.1%494493-----------374370366362----
    LT Debt, Non Current0.1%5935931,0851,0841,0831,0821,0811,0801,0791,0781,0771,0761,0751,0741,073487486844839835830
Shareholder's Equity1.1%4,9524,8974,7834,6594,6034,5694,5004,3864,2664,2614,2374,1624,1014,0543,2373,2403,1223,0742,9612,9372,968
  Retained Earnings3.2%-621-641-682-738-789-788-777-804-930-867-831-844-861-883-1,668-1,639-1,720-1,735-1,790-1,753-1,694
  Additional Paid-In Capital1.2%5,6125,5435,4945,4185,4055,3365,2735,2065,1925,1345,0845,0114,9934,9384,8864,8554,8334,7834,7444,6834,670
Accumulated Depreciation-100.0%-851829807802782762741721------------
Shares Outstanding0.1%189188188188186185185184183183182182---------
Float---10,100---9,000---8,400---13,900---8,100--
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations-79.7%27,483135,64670,062-73,9326,786158,32156,226-45,43111,18097,06082,784113,512-13,38486,20627,737-15,19457,34370,125-24,338-54,86849,374
  Share Based Compensation13.4%54,85548,38750,16253,69546,73454,66347,07847,83343,89149,02654,84349,50347,58650,16944,96246,99438,10239,17339,82942,76136,558
Cashflow From Investing-41.8%-64,963-45,79929,530-30,012-54,710-23,402-29,69987,782-55,421-119,847-120,257-70,78811,027106,699-248,75177,404-48,89648,67819,671-50,479-70,963
Cashflow From Financing1475.6%10,840-78811,963-40,74210,8697,541-11,780-25,28014,396-1,03110,951-24,364-366,1553,256563,688-19,6714,042-1,975-51,760-24,981-366,362
  Buy Backs---------------50,000------

BMRN Income Statement

2023-12-31
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
REVENUES:   
Total revenues$ 2,419,226$ 2,096,039$ 1,846,275
OPERATING EXPENSES:   
Cost of sales514,854483,669470,515
Research and development746,773649,606628,793
Selling, general and administrative937,291854,009759,375
Intangible asset amortization and contingent consideration62,21167,19369,933
Gain on sale of nonfinancial assets, net0(108,000)0
Total operating expenses2,261,1291,946,4771,928,616
INCOME (LOSS) FROM OPERATIONS158,097149,562(82,341)
Interest income58,33918,03410,482
Interest expense(17,335)(15,970)(15,337)
Other income (expense), net(10,538)(2,050)11,846
INCOME (LOSS) BEFORE INCOME TAXES188,563149,576(75,350)
Provision for (benefit from) income taxes20,9188,015(11,270)
NET INCOME (LOSS)$ 167,645$ 141,561$ (64,080)
EARNINGS (LOSS) PER SHARE, BASIC (in dollars per share)$ 0.89$ 0.76$ (0.35)
EARNINGS (LOSS) PER SHARE, DILUTED (in dollars per share)$ 0.87$ 0.75$ (0.35)
Weighted-average common shares outstanding, basic (in shares)187,834185,266182,852
Weighted average common shares outstanding, diluted (in shares)191,595188,963182,852
Net product revenues   
REVENUES:   
Total revenues$ 2,372,538$ 2,042,025$ 1,783,498
Royalty and other revenues   
REVENUES:   
Total revenues$ 46,688$ 54,014$ 62,777

BMRN Balance Sheet

2023-12-31
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 755,127$ 724,531
Short-term investments318,683567,006
Accounts receivable, net633,704461,316
Inventory1,107,183894,083
Other current assets141,391104,521
Total current assets2,956,0882,751,457
Noncurrent assets:  
Long-term investments611,135333,835
Property, plant and equipment, net1,066,1331,073,366
Intangible assets, net294,701338,569
Goodwill196,199196,199
Deferred tax assets1,545,8091,505,412
Other assets171,538176,236
Total assets6,841,6036,375,074
Current liabilities:  
Accounts payable and accrued liabilities683,147572,959
Short-term convertible debt, net493,8770
Short-term contingent consideration015,925
Total current liabilities1,177,024588,884
Noncurrent liabilities:  
Long-term convertible debt, net593,0951,083,019
Other long-term liabilities119,935100,015
Total liabilities1,890,0541,771,918
Stockholders’ equity:  
Common stock, $0.001 par value: 500,000,000 shares authorized; 188,598,154 and 186,250,719 shares issued and outstanding, respectively189186
Additional paid-in capital5,611,5625,404,895
Company common stock held by the Nonqualified Deferred Compensation Plan(9,860)(8,859)
Accumulated other comprehensive loss(28,788)(3,867)
Accumulated deficit(621,554)(789,199)
Total stockholders’ equity4,951,5494,603,156
Total liabilities and stockholders’ equity$ 6,841,603$ 6,375,074
BMRN
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A; BMN 331, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial for people living with Hereditary Angioedema (HAE); and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.
 CEO
 WEBSITEbiomarin.com
 INDUSTRYBiotechnology
 EMPLOYEES3082

BioMarin Pharmaceutical Inc Frequently Asked Questions


What is the ticker symbol for BioMarin Pharmaceutical Inc? What does BMRN stand for in stocks?

BMRN is the stock ticker symbol of BioMarin Pharmaceutical Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of BioMarin Pharmaceutical Inc (BMRN)?

As of Fri Apr 12 2024, market cap of BioMarin Pharmaceutical Inc is 17.41 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BMRN stock?

You can check BMRN's fair value in chart for subscribers.

What is the fair value of BMRN stock?

You can check BMRN's fair value in chart for subscribers. The fair value of BioMarin Pharmaceutical Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of BioMarin Pharmaceutical Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for BMRN so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is BioMarin Pharmaceutical Inc a good stock to buy?

The fair value guage provides a quick view whether BMRN is over valued or under valued. Whether BioMarin Pharmaceutical Inc is cheap or expensive depends on the assumptions which impact BioMarin Pharmaceutical Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BMRN.

What is BioMarin Pharmaceutical Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 12 2024, BMRN's PE ratio (Price to Earnings) is 103.82 and Price to Sales (PS) ratio is 7.19. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BMRN PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on BioMarin Pharmaceutical Inc's stock?

In the past 10 years, BioMarin Pharmaceutical Inc has provided 0.047 (multiply by 100 for percentage) rate of return.